CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Xenon gas +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02071394
NCT02071394Phase 2Completed

Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth: A Randomised Pilot Outcomes Study (COOLXENON3 Study)

University Hospitals Bristol and Weston NHS Foundation Trust·interventional·Posted Feb 25, 2014·Updated Jan 5, 2023

In Brief

A Phase 2 clinical trial evaluating Xenon gas and Whole body cooling for Hypoxic Ischaemic Encephalopathy. Completed, enrolled 50 participants across 2 sites.

Detailed Summary

This study examines the effect of inhaled xenon gas in the treatment of newborn infants with hypoxic-ischemic encephalopathy (HIE) in combination with cooling, which is the standard treatment for this condition. The hypothesis is that the xenon + cooling combination will produce better neuroprotection than the standard treatment of cooling alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2014
Enrollment StartMar 1, 2014
Primary CompletionOct 7, 2019
Study CompletionApr 15, 2020
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 12.4 years ago

Interventions

Xenon gasdrug

Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.

Whole body coolingother

Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.